CLINICAL TRIAL SUMMARY

MDACC Study No:ID03-0111 (clinicaltrials.gov NCT No: NCT00082706)
Title:Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant
Principal Investigator:Arlene Siefker-Radtke
Treatment Agent:5-Fluorouracil; Cisplatin; Gemcitabine; Leucovorin
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if treatment with a
combination of 4 chemotherapy drugs can help to shrink or slow the growth of
adenocarcinoma. The drugs used in the combination chemotherapy are:
5-fluorouracil (5FU), leucovorin, gemcitabine, and cisplatin.

Hide details for General InformationGeneral Information

Disease Group:Bladder
Phase of Study:Phase II
Treatment Agents:5-Fluorouracil
Cisplatin
Gemcitabine
Leucovorin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:4-5 days every 3 weeks to receive chemotherapy.
Supported By:N/A
Return Visit:Every 2 cycles (6 weeks)
Home Care:Chemotherapy may be given at home.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Arlene Siefker-Radtke
Dept:Genitourinary Medical Oncology
For Clinical Trial Enrollment:713-792-2830
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults